Abivax (AAVXF) Current Assets (2021 - 2026)

Abivax has reported Current Assets for 6 years, with the latest figure at $600.9 million in Q1 2026.

• On a quarterly basis, Current Assets rose 330.56% year-over-year to $600.9 million in Q1 2026; TTM through Mar 2026 was $600.9 million, a 330.56% increase from a year earlier, with the FY2025 full-year figure at $641.7 million, up 251.84% from the prior year.
• Current Assets was $600.9 million for Q1 2026 at Abivax, down from $641.7 million in the prior quarter.
• The five-year high for Current Assets was $724.0 million in Q3 2025, with the low at $36.9 million in Q4 2022.
• Average Current Assets over 5 years is $332.5 million, with a median of $261.7 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Current Assets surged 733.54% in 2023, then plunged 62.75% in 2025.
• Over 5 years, Current Assets stood at $36.9 million in 2022, then soared by 733.54% to $307.7 million in 2023, then sank by 40.73% to $182.4 million in 2024, then soared by 251.84% to $641.7 million in 2025, then declined by 6.36% to $600.9 million in 2026.
• The last three Current Assets figures came in at $600.9 million (Q1 2026), $641.7 million (Q4 2025), and $724.0 million (Q3 2025), per Business Quant data.